Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PHARMACOECONOMIC CLAIMS LIMITED TO "ECONOMIC CONSEQUENCES" IN FDA REFORM AMENDMENT; PHASE IV, PET DRUGS AMONG TOPICS MODIFIED FROM MARK-UP OF S 830

Executive Summary

The scope of pharmacoeconomic claims allowed under the Senate FDA reform bill would be limited to "the economic consequences, including the costs of the represented health outcomes" of a drug, under the floor version of the S 830 being debated the week of Sept. 8.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030806

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel